CClinicalTrials.gg
Sign In
Active, not recruitingNCT07428096Updated Feb 23, 2026

A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease

A Phase 1 interventional study of PALI-2108 in Fibrostenotic Crohn's Disease, sponsored by Palisade Bio. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Palisade Bio · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD). The study will assess molecular, cellular, and histologic changes in intestinal tissue and peripheral blood following short-term oral administration of PALI-2108.

Eligible participants with FSCD will undergo paired ileal pinch biopsies and peripheral blood collection at baseline and after 14 days of PALI-2108 treatment. The primary objective is to elucidate the mechanism of action of PALI-2108 in modulating inflammatory and fibrotic pathways relevant to FSCD pathobiology. Analyses will include single-nucleus RNA sequencing (snRNA-seq) of intestinal biopsies and single-cell RNA sequencing (scRNA-seq) of PBMCs to profile treatment-induced transcriptomic changes across immune and stromal cell populations.

The FSCD cohort is part of a larger, multi-part study that also includes a completed Phase 1a first-in-human portion in healthy volunteers and an ulcerative colitis (UC) cohort evaluating clinical and biomarker responses to PALI-2108 treatment.

Read the detailed description

This Phase 1b exploratory study will investigate the pharmacodynamic and mechanistic effects of short-term oral administration of PALI-2108, a selective phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD). The FSCD cohort builds upon the safety, tolerability, and pharmacokinetic findings from the completed Phase 1a first-in-human study and complements the ongoing ulcerative colitis (UC) cohort that assesses clinical and biomarker responses to PALI-2108 in active disease.

Fibrostenotic Crohn's disease is characterized by chronic inflammation and progressive fibrosis of the intestinal wall leading to luminal narrowing, strictures, and obstructive symptoms. Current medical therapies inadequately address the fibrotic component of disease, underscoring the need for interventions targeting both immune and stromal pathways. PDE4 inhibition represents a validated anti-inflammatory approach with emerging evidence for modulation of profibrotic signaling.

In this study, patients with ileal or ileocolonic FSCD will receive PALI-2108 orally once daily for 14 days. Paired ileal pinch biopsies and peripheral blood samples will be collected at baseline (Day 1) and at the end of treatment (Day 14). The primary objective is to characterize molecular and cellular changes induced by PDE4 inhibition in intestinal and immune compartments.

Transcriptomic profiling will be performed using single-nucleus RNA sequencing (snRNA-seq) on intestinal biopsies and single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs). Analyses will evaluate treatment-associated changes in gene expression, cell-type composition, and pathway activation, with a focus on immune, epithelial, fibroblast, and myofibroblast populations implicated in FSCD pathology. Secondary and exploratory endpoints will include assessment of safety, tolerability, pharmacokinetics, and biomarker correlations across tissue and blood compartments.

Data from this FSCD cohort are expected to provide mechanistic insights into the biological effects of PDE4 inhibition in fibrostenotic disease and to inform dose selection, biomarker strategies, and patient segmentation for subsequent clinical development programs of PALI-2108.

02

Conditions studied

  • Fibrostenotic Crohn's Disease

Keywords

  • Phosphodiesterase 4 Inhibitor
  • PDE4 Inhibition
  • Intestinal Fibrosis
  • Inflammatory Bowel Disease (IBD)
  • Ileal Stricture
  • Crohn's Disease
  • PALI-2108
  • Oral PDE4 Inhibitor
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Provision of signed and dated informed consent form (ICF)
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Aged at least 18 years but not older than 60 years
  4. Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively
  5. Non- or ex-smoker
  6. Healthy adult male or female
  7. Have no clinically significant (CS) diseases captured in the medical history or evidence of CS findings on the physical examination (including vital signs) and/or ECG, as determined by an Investigator
  8. Provision of signed and dated ICF
  9. Stated willingness to comply with all study procedures and availability for the duration of the study

  10. If male, meets one of the following criteria:

    1. Is able to procreate and agrees to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last study drug administration. An acceptable method of contraception includes one of the following:

      • Abstinence from heterosexual intercourse
      • Male condom with spermicide or male condom with a vaginal spermicide Or
    2. Is unable to procreate; defined as surgically sterile

    If female, meets one of the following criteria:

    1. Is of childbearing potential and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:

      • Abstinence from heterosexual intercourse from 14 days prior to the Screening visit through to at least 30 days after the last dose of the study drug

      • Use of 1 highly effective method in combination with 1 effective method of contraception.

        • The following are examples of highly effective contraceptive methods, used from at least 28 days prior to the Screening visit through to at least 30 days after the last dose of the study drug:
      • Systemic contraceptives (combined birth control pills, injectable/implant/insertable hormonal birth control products, or transdermal patch)
      • Intrauterine device

      • Male partner vasectomized at least 6 months prior to the Screening visit

        • The following are examples of effective contraceptive methods, used from the Screening visit through to at least 30 days after the last dose of the study drug:
      • Male condom with spermicide
      • Female condom, or cervical cap, or diaphragm, each used with spermicide
      • Contraceptive sponge
    2. Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation), or is in a postmenopausal state (ie, at least 1 year without messes and without an alternative medical condition prior to the Screening visit)

  11. Diagnosis of ileal or ileocolonic CD based on supporting guideline criteria established at least 3 months prior to Screening, i.e.:

    c) Clinically symptomatic fibrostenosing Crohn's disease, defined by ≥1 obstructive symptom attributable to the index ileal stricture within the prior 12 weeks and corroborated at Screening by the Stricturing Crohn's Disease patient-reported questionnaire (SPRO).

    d) Symptoms must be accompanied by an ileal stricture within reach of the endoscope.

  12. Screening IUS confirms the presence of at least 1 stricture in the terminal ileum or proximal colon, within reach of an endoscope (passable or non-passable). Strictures should be noncritical, naïve or anastomotic stricture(s), caused by CD and confirmed by endoscopy.
  13. Stable background therapy for CD and agree to maintain background therapy for the study duration.
  14. Patients may or may not experience stricture related symptoms, such as abdominal pain, during Screening
  15. Willingness to follow a stable diet during the study

Exclusion criteria

Exclusion Criteria

  1. Female who is lactating
  2. Female who is pregnant according to the pregnancy test at Screening or Day -1
  3. History of significant hypersensitivity to PALI-2108 or any other PDE-4 inhibitor (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  4. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability or transit
  5. Presence of history of renal disease
  6. History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, or dermatologic disease
  7. An active infection or a recent history of serious infections 30 days prior to first study drug administration
  8. Presence of CS vital sign and/or ECG abnormalities (based on the average of triplicate ECG readings) at the Screening visit, as defined by medical judgment
  9. Major surgery in the 4 weeks prior to the first study drug administration
  10. Vaccination with any live vaccine within 4 weeks prior to study drug administration
  11. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  12. Any CS illness in the 28 days prior to the first study drug administration
  13. Use of St. John's wort in the 28 days prior to the first study drug administration
  14. Any history of tuberculosis
  15. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first study drug administration
  16. Positive Screening results to HIV antigen/antibody (Ag/Ab) combo, hepatitis B surface antigen, or hepatitis C virus tests
  17. Any other CS abnormalities in laboratory test results at Screening that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data
  18. Inclusion in a previous group for this clinical study
  19. Intake of PALI-2108 in the 28 days prior to the first study drug administration
  20. Intake of an investigational drug in the 28 days prior to the first study drug administration
  21. Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
  22. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration
  23. History or current diagnosis of UC, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug-induced colitis, idiopathic colitis (ie, colitis not consistent with CD), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption.
  24. CD related complications (previous extensive small bowel resection, ileorectal anastomosis, proctocolectomy, short bowel syndrome, ileostomy [diverting or end], colostomy, small bowel stoma, ileoanal pouch, inactive fistulae in or adjacent to an ileal stricture, anal and perianal stricture, active intra-abdominal or perianal abscess that has not been appropriately treated, abscess in relation to the stricture, toxic megacolon, very severe inflammation, or presence of deep ulceration in the colon or terminal ileum).
  25. Ileitis not associated with CD (e.g., ileitis associated with infections, spondyloarthropathies, ischemia, etc.).
  26. Strictures that cannot be reached by ileocolonoscopy
  27. Severe FSCD based on symptoms, or unstable disease
  28. Expected to require hospitalization, endoscopic balloon dilation, surgical resection, or additional therapy during the study
  29. Receiving cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks of screening or Janus kinase inhibitor therapy within 4 weeks of screening.
  30. Current or history of vasculitis, valvulopathy or large vessel disorder or major abnormalities documented by cardiac echocardiography with Doppler
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    FSCD Arm

    PALI-2108 All participants receive once-daily oral PALI-2108 for 14 days in the fed state. Two sentinel subjects receive a titrated regimen from 5 mg to 20 mg. After 7 days of sentinel dosing, the Safety Review Committee (SRC) reviews safety data and assigns the subsequent two patients to a target dose of 25 mg, with a predefined titration schedule. If the 25 mg dose is judged to be safe, all remaining subjects receive a target daily dose of 30 mg, also with a predefined titration scheme. Dose reductions may occur if safety profile is not judged adequate by SRC. Dosing is site-administered except on protocol-specified days when self-administration at home is permitted.

    Drug: PALI-2108

Interventions

  • DrugPALI-2108

    Oral PALI-2108 administered once daily for 14 days. Sentinel subjects titrate from 5 mg to 20 mg. Subsequent patients receive a target dose between 10-30 mg based on SRC review, following protocol-specified titration schedules. Dose reductions are permitted for safety. All doses are taken in the fed state. PALI-2108 is an oral, gut-activated PDE4 inhibitor prodrug designed to release its active metabolite (PALI-0008) locally via bacterial β-glucuronidase. This targeted delivery limits systemic exposure and reduces CNS-related effects associated with systemic PDE4 inhibitors, providing localized anti-inflammatory and anti-fibrotic activity in intestinal tissue.

05

What researchers measure

Primary outcomes

  1. Safety and tolerability of PALI-2108 administered for 14 days.

    Adverse events in FSCD patients receiving PALI-2108

    Time frame: 14 days

  2. Safety and tolerability of PALI-2108

    Incidence of clinically significant laboratory abnormalities

    Time frame: 14 Days

  3. Safety and tolerability of PALI-2108

    Incidence of clinically significant ECG findings

    Time frame: 14 Days

  4. Safety and tolerability of PALI-2108

    Incidence of clinically significant vital signs findings

    Time frame: 14 Days

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Maximum plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708 ) following dosing with PALI-2108

    Time frame: Day 1

  2. Concentration at 12 hours (C12)

    Plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) at 12 hours following dosing with PALI-2108

    Time frame: Day 1

  3. Time to Cmax (Tmax)

    Time to reach maximum plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708)

    Time frame: Day 1

  4. Area under the plasma concentration-time curve (AUC0-24)

    Area under the plasma concentration-time curve of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) during the first 24 hours period after first dosing with PALI-2108

    Time frame: Day 1

  5. Terminal half-life (t1/2)

    Plasma elimination half-life of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) after first dose of PALI-2108

    Time frame: Day 1 and Day 13

  6. Trough plasma concentration (Ctrough)

    Plasma concentration of PALI-2108 and its metabolites (PALI-0008 and PALI-070) measured in the morning, before PALI-2108 dosing

    Time frame: Day 2 through Day 14

  7. Maximal concentration at steady state (Css)

    Maximal plasma concentration of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) measured at plasma drug steady state

    Time frame: Day 13

  8. Area under the plasma concentration-time curve (AUC0-12)

    Area under the plasma concentration-time curve of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) during the first 12 hours period after dosing with PALI-2108

    Time frame: Day 13

  9. Area under the plasma concentration-time curve (AUC0-8)

    Area under the plasma concentration-time curve of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) during the first 8 hours period after last dosing with PALI-2108

    Time frame: Day 14

  10. Tissue concentration

    Concentrations of of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) in ileal, ascending and descending colonic tissue at plasma steady state.

    Time frame: Day 14

  11. Tissue/plasma concentration ratio

    Ratio between tissue and plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) in ileal, ascending and descending colonic tissue at plasma steady state.

    Time frame: Day 14

Other outcomes

  1. Change in PDE-4 expression and related molecular pathways in ileal tissue.

    Expression of inflammatory and fibrotic biomarkers via snRNA-seq and bulk RNA-seq (log fold change)

    Time frame: Baseline to Day 14.

  2. Change in endoscopic severity using the Simple Endoscopic Score for Crohn's Disease (SES-CD).

    Change in endoscopic severity using the Simple Endoscopic Score for Crohn's Disease (SES-CD).

    Time frame: Screening to Day 14 ileocolonoscopy

  3. Change in intestinal ultrasound (IUS) parameters of ileal strictures (inflammatory and fibrotic features).

    Change in intestinal ultrasound (IUS) parameters of ileal strictures (inflammatory and fibrotic features).

    Time frame: Baseline to Day 13

  4. Change in symptom scores based on the Stricturing Crohn's Disease Questionnaire (SPRO v1.0).

    Change in symptom scores based on the Stricturing Crohn's Disease Questionnaire (SPRO v1.0).

    Time frame: Screening to Day 13

  5. Changes in fibrosis and inflammation biomarkers in plasma.

    hsCRP, CPa9-HNE, PRO-C3, PRO-C6, PRO-C11, PRO-C16, XTX-III\_HP, C3M\_HP, C4M\_HP, C7M, PRO-C22, VICM\_HP, and transcriptomic signatures from PBMC mRNA-seq

    Time frame: Baseline to Day 13.

  6. Change From Baseline in Histology Score Using Robarts Histology Index (RHI) in ileum biopsy tissue

    The RHI is an evaluative index, derived from the Geboes score and is designed to be reproducible and responsive to clinically meaningful change in disease activity over time. The total RHI score ranges from 0 (no disease activity) to 33 (severe disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline to Day 14

  7. Change From Baseline in Histology Score Using Nancy Histology Index (NHI) in ileum biopsy tissue

    NHI is a validated index for assessing histological disease activity in UC. It is composed of three histological items defining five grades of disease activity: absence of significant histological disease (Grade 0), chronic inflammatory infiltrate with no acute inflammatory infiltrate (Grade 1), mildly active disease (Grade 2), moderately active disease (Grade 3), and severely active disease (Grade 4). The presence of ulceration on the biopsy specimen corresponds to severely active disease (Grade 4). A decrease of the NHI grading system to Grades 0 or 1 would indicate improvement.

    Time frame: Baseline to Day 14

  8. Change From Baseline in Histology Score Using Global Histologic Disease Activity Score (GHAS) in ileum biopsy tissue

    GHAS is a validated histologic scoring assessment that evaluates the overall severity of mucosal inflammation in ulcerative colitis based on microscopic features (e.g., architectural distortion, chronic inflammatory infiltrate, neutrophils, erosions/ulceration). Minimum score: 0, Maximum score: 22. Higher scores indicate greater histologic disease activity.

    Time frame: Baseline to Day 14

  9. Change From Baseline in Ileum Biopsy Tissue Histological Assessment of Fibrocytes/Fibroblasts

    The assessment measures the density and distribution of stromal cells involved in extracellular matrix production, wound healing, and fibrotic remodeling. There is no fixed minimum or maximum value. Higher values indicate increased stromal activation or fibrogenic activity.

    Time frame: Baseline to Day 14

  10. Change From Baseline in Ileum Biopsy Tissue Histological Assessment of Collagen

    The assessment measures the extent and distribution of extracellular matrix collagen as an indicator of tissue remodeling or fibrotic activity. There is no fixed minimum or maximum value. Higher values reflect greater collagen accumulation.

    Time frame: Baseline to Day 14

  11. Change From Baseline in Ileum Biopsy Tissue Histological Assessment of Muscularis Mucosa Thickening

    This measure reflects structural remodeling of the mucosal wall, often associated with chronic inflammation, altered motility, or early fibrotic change. There is no fixed minimum or maximum value. Higher values indicate greater thickening of the muscularis mucosa.

    Time frame: Baseline to Day 14

  12. Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD)

    The SES-CD is a validated endoscopic scoring system that quantifies the severity of Crohn's disease based on colonoscopy findings. The minimum score is 0 (no endoscopic disease activity); the maximum score is 56 (severe ulceration, extensive affected surface, strictures in all segments).

    Time frame: Baseline to Day 14

  13. Change From Baseline in intestinal ultrasound (IUS) parameters of ileal strictures (inflammatory and fibrotic features)

    IUS assessment of ileal strictures relies on quantitative measures (e.g., bowel wall thickness) and semi-quantitative features. The units are mm with higher values indicating more severity.

    Time frame: Baseline to Day 14

  14. Change From Baseline in symptom scores based on the Stricturing Crohn's Disease Questionnaire (SPRO v1.0)

    The Stricturing Crohn's Disease Patient Reported Outcome (SPRO v1.0) is a validated PRO instrument developed by the STAR Consortium to measure symptoms and impacts associated with small bowel strictures in Crohn's disease. The instrument has a unitless score ranging from 0 (no symptoms) to 12 (worst symptoms).

    Time frame: Baseline to Day 13

  15. Change From Baseline In Biomarkers Including

    The Stricturing Crohn's Disease Patient Reported Outcome (SPRO v1.0) is a validated PRO instrument developed to measure symptoms and impacts associated with small bowel strictures in Crohn's disease. The instrument has a unitless score ranging from 0 (no symptoms) to 12 (worst symptoms).

    Time frame: Baseline to Day 13

  16. Change From Baseline In Biomarkers Including Serum High Sensitivity C Reactive Protein (hsCRPp)

    hsCRP units of measure are mg/L with higher values indicating worse systemic inflammation.

    Time frame: Baseline to Day 13

  17. Change From Baseline In Biomarkers Including Serum Neutrophil Elastase-Degraded Type IX Collagen Fragment (Cpa9-HNE)

    CPa9-HNE units of measure are ng/mL with higher values indicating worse neutrophil-driven tissue injury.

    Time frame: Baseline to Day 13

  18. Change From Baseline In Biomarkers Including Serum Type III Collagen Formation Fragment (PRO-C3)

    PRO-C3 units of measure are ng/mL with higher values indicating worse collagen III formation / fibrogenesis.

    Time frame: Baseline to Day 13

  19. Change From Baseline In Biomarkers Including Serum Type VI Collagen Formation Fragment (Endotrophin) (PRO-C6)

    PRO-C6 units of measure are ng/mL with higher values indicating worse collagen VI formation / fibrosis.

    Time frame: Baseline to Day 13

  20. Change From Baseline In Biomarkers Including Serum Type XI Collagen Formation Fragment (PRO-C11)

    PRO-C11 units of measure are ng/mL with higher values indicating worse collagen XI formation / remodeling.

    Time frame: Baseline to Day 13

  21. Change From Baseline In Biomarkers Including Serum Type XVI Collagen Formation Fragment (PRO-C16)

    PRO-C16 units of measure are ng/mL with higher values indicating worse collagen XVI formation / basement membrane remodeling.

    Time frame: Baseline to Day 13

  22. Change From Baseline In Biomarkers Including Serum Cross Linked Type III Collagen Fragment (High Precision) (XTX-III_HP)

    XTX-III\_HP units of measure are ng/mL with higher values indicating worse cross linked collagen III turnover.

    Time frame: Baseline to Day 13

  23. Change From Baseline In Biomarkers Including Serum MMP Degraded Type III Collagen Fragment (High Precision) (C3M_HP)

    C3M\_HP units of measure are ng/mL with higher values indicating worse MMP mediated collagen III degradation.

    Time frame: Baseline to Day 13

  24. Change From Baseline In Biomarkers Including Serum MMP Degraded Type IV Collagen Fragment (High Precision) (C4M_HP)

    C4M\_HP units of measure are ng/mL with higher values indicating worse MMP mediated collagen IV degradation; basement membrane injury.

    Time frame: Baseline to Day 13

  25. Change From Baseline In Biomarkers Including Serum MMP Degraded Type VII Collagen Fragment (C7M)

    C7M units of measure are ng/mL with higher values indicating worse collagen VII degradation; epithelial barrier injury.

    Time frame: Baseline to Day 13

  26. Change From Baseline In Biomarkers Including Serum Type XXII Collagen Formation Fragment (PRO-C22)

    PRO-C22 units of measure are ng/mL with higher values indicating worse collagen XXII formation; epithelial-stromal interface remodeling.

    Time frame: Baseline to Day 13

  27. Change From Baseline In Biomarkers Including Serum Citrullinated And MMP Degraded Vimentin Fragment (High Precision) (VICM_HP)

    VICM\_HP units of measure are ng/mL with higher values indicating worse macrophage activation; citrullinated vimentin turnover.

    Time frame: Baseline to Day 13

  28. Change From Baseline In Biomarkers in PBMC and FSCD lesions (inflammatory region and fibrotic region including Whole Blood Composite Gene Expression Signature)

    Transcriptomic signatures use a unitless composite score with no fixed range, The change of values is gene dependent and can be indicating disease progression by change in either direction

    Time frame: Baseline to Day 13

06

Study locations

1 site
  • Altasciences
    Montreal, Quebec H3P3H5, Canada
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07428096
Lead sponsor
Palisade Bio
Collaborators
Altasciences Company Inc.
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Oct 17, 2025
Primary completion
Jan 30, 2026
Completion
Mar 15, 2026 (estimated)
Last update
Feb 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Inflammatory Bowel Diseases→

Other studies from this sponsor

Palisade Bio

Start the discussion